New hope for lung cancer: drug may keep disease in check after standard therapy

NCT ID NCT07161388

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 21 times

Summary

This study looks at whether the drug durvalumab can help control limited-stage small-cell lung cancer after initial chemoradiation. About 200 adults in China whose cancer did not worsen after standard treatment will receive durvalumab. Researchers will track how long the cancer stays under control and how long patients can stay on the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIMITED STAGE SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Beijing, China

  • Research Site

    RECRUITING

    Cangzhou, China

  • Research Site

    RECRUITING

    Dongguan, China

  • Research Site

    RECRUITING

    Fuzhou, China

  • Research Site

    RECRUITING

    Guangzhou, China

  • Research Site

    RECRUITING

    Huzhou, China

  • Research Site

    RECRUITING

    Jinan, 250117, China

  • Research Site

    RECRUITING

    Jinan, China

  • Research Site

    RECRUITING

    Nanjing, China

  • Research Site

    RECRUITING

    Nanning, China

  • Research Site

    RECRUITING

    Ningbo, China

  • Research Site

    RECRUITING

    Shanghai, China

  • Research Site

    RECRUITING

    Shenyang, China

  • Research Site

    RECRUITING

    Shijiazhuang, China

  • Research Site

    RECRUITING

    Taiyuan, China

  • Research Site

    RECRUITING

    Tianjing, China

  • Research Site

    TERMINATED

    Tianjing, China

  • Research Site

    RECRUITING

    Wuhan, China

  • Research Site

    RECRUITING

    Wuxi, China

  • Research Site

    RECRUITING

    Yangzhou, China

  • Research Site

    RECRUITING

    Zhengzhou, China

Conditions

Explore the condition pages connected to this study.